Skip to main content

Advertisement

SpringerLink
Log in

Rituximab for the management of idiopathic membranous nephropathy: a meta-analysis

  • Nephrology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to evaluate the efficacy of rituximab therapy in the management of idiopathic membranous nephropathy (IMN).

Methods

After literature search, data from eligible studies were used to perform random-effects meta-analyses to estimate remission rates and changes in proteinuria at the latest follow-up after rituximab therapy. The outcomes were used for metaregression to identify the factors affecting the efficacy of rituximab.

Results

Twenty-one studies were included in the analysis (602 patients; age 50 years [95% CI 46.8, 53.3]; 30% females [95% CI 23, 31]). Follow-up duration was 20.3 months [95% CI 17.1, 23.5]. Remission rate (67% [95% CI 61, 73]) was higher in studies with below average baseline proteinuria (76% [95% CI 61, 88]) than in studies with above average baseline proteinuria (61% [95% CI 54, 68]). The complete and partial remission rates were 26% [95% CI 20, 33] and 37% [95% CI 31, 43], respectively. Rituximab therapy significantly reduced proteinuria (mean difference between final and baseline values: − 4.90 g/day [95% CI − 6.18, − 3.63]; p < 0.00001; % reduction: 62% [95% CI 57, 68]). The reduction in proteinuria was inversely associated with baseline serum albumin levels (p = 0.021) and the estimated glomerular filtration rate (p < 0.00001) and was positively associated with baseline proteinuria (p < 0.00001). The remission rate or decrease in proteinuria was not significantly related to the anti-PLA2R antibody status or previous immunosuppressant therapy.

Conclusion

Rituximab therapy in IMN patients can provide approximately 67% remission rate. The reduction in proteinuria was greater in patients who had higher baseline proteinuria.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Availability of data and materials

Available upon request

References

  1. Ruggenenti P, Fervenza FC, Remuzzi G (2017) Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol 13:563–579

    Article  CAS  PubMed  Google Scholar 

  2. Ponticelli C, Glassock RJ (2014) Glomerular diseases: membranous nephropathy–a modern view. Clin J Am Soc Nephrol 9:609–616

    Article  PubMed  Google Scholar 

  3. Couser WG (2017) Primary membranous nephropathy [correction in: Clin J Am Soc Nephrol]. Clin J Am Soc Nephrol 12(6):983–997

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. McGrogan A, Franssen CF, de Vries CS (2011) The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 26:414–430

    Article  PubMed  Google Scholar 

  5. Couser WG, Salant DJ (1980) In situ immune complex formation and glomerular injury. Kidney Int 17:1–13

    Article  CAS  PubMed  Google Scholar 

  6. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ (2009) M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361:11–21

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Tomas NM, Beck LH, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, Dolla G, Hoxha E, Helmchen U, Dabert-Gay AS, Debayle D, Merchant M, Klein J, Salant DJ, Stahl RAK, Lambeau G (2014) Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 371:2277–2287

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Francis JM, Beck LH Jr, Salant DJ (2016) Membranous nephropathy: a journey from bench to bedside. Am J Kidney Dis 68:138–147

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Hogan JJ, Markowitz GS, Radhakrishnan J (2015) Drug-induced glomerular disease: immune-mediated injury. Clin J Am Soc Nephrol 10:1300–1310

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Xu X, Wang G, Chen N, Lu T, Nie S, Xu G, Zhang P, Luo Y, Wang Y, Wang X, Schwartz J, Geng J, Hou FF (2016) Long-term exposure to air pollution and increased risk of membranous nephropathy in China. J Am Soc Nephrol 27(12):3739–3746

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Glassock RJ (2003) Diagnosis and natural course of membranous nephropathy. Semin Nephrol 23:324–332

    Article  PubMed  Google Scholar 

  12. Radhakrishnan J, Cattran DC (2012) The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines–application to the individual patient. Kidney Int 82(8):840–856

    Article  PubMed  Google Scholar 

  13. Cravedi P, Remuzzi G, Ruggenenti P (2014) Rituximab in primary membranous nephropathy: first-line therapy, why not? Nephron Clin Pract 128:261–269

    Article  CAS  PubMed  Google Scholar 

  14. Cravedi P (2017) Rituximab in membranous nephropathy: not all studies are created equal. Nephron 135:46–50

    Article  CAS  PubMed  Google Scholar 

  15. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P (2013) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 30 Mar 2020

  16. Nyaga VN, Arbyn M, Aerts M (2014) Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health 72(1):39. https://doi.org/10.1186/2049-3258-72-39

    Article  PubMed  PubMed Central  Google Scholar 

  17. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors) (2019) Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane. https://training.cochrane.org/handbook/current/chapter-10

  18. Harbord RA, Higgins JPT (2008) Meta-regression in Stata. Stata J 8(4):493–519

    Article  Google Scholar 

  19. Ales Rigler A, Jerman A, Orsag A, Kojc N, Kovač D, Škoberne A, Borštnar Š, Večerić Haler Ž, Avguštin N, Kveder R, Ferluga D, Vizjak A, Lindič J (2017) Rituximab for the treatment of membranous nephropathy: a single-center experience. Clin Nephrol 88:27–31

    Article  PubMed  Google Scholar 

  20. Bagchi S, Subbiah AK, Bhowmik D, Mahajan S, Yadav RK, Kalaivani M, Singh G, Dinda A, Kumar Agarwal S (2018) Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience. Clin Kidney J 11:337–341

    Article  CAS  PubMed  Google Scholar 

  21. Busch M, Ruster C, Schinköthe C, Gerth J, Wolf G (2013) Rituximab for the second- and third-line therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy. Clin Nephrol 80:105–113

    Article  CAS  PubMed  Google Scholar 

  22. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G (2007) Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2:932–937

    Article  CAS  PubMed  Google Scholar 

  23. Cravedi P, Sghirlanzoni MC, Marasà M, Salerno A, Remuzzi G, Ruggenenti P (2011) Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. Am J Nephrol 33:461–468

    Article  CAS  PubMed  Google Scholar 

  24. El-Zoghby ZM, Grande JP, Fraile MG, Norby SM, Fervenza FC, Cosio FG (2009) Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies. Am J Transplant 9:2800–2807

    Article  CAS  PubMed  Google Scholar 

  25. Esposito P, Grosjean F, Mangione F, Domenech MV, Rampino T (2018) Rituximab in primary membranous nephropathy: beyond a B-cell-centered paradigm? Clin Exp Nephrol 22:208–209

    Article  PubMed  Google Scholar 

  26. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, Leung N, Cohen IM, Wochos DN, Bergstralh E, Hladunewich M, Cattran DC (2008) Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 73:117–125

    Article  CAS  PubMed  Google Scholar 

  27. Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LJ, Li X, Cattran DC (2010) Mayo Nephrology Collaborative Group: rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 5:2188–2198

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, Jüni P, Cattran DC (2019) MENTOR Investigators: rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 381:36–46

    Article  CAS  PubMed  Google Scholar 

  29. Fiorentino M, Tondolo F, Bruno F, Infante B, Grandaliano G, Gesualdo L, Manno C (2016) Treatment with rituximab in idiopathic membranous nephropathy. Clin Kidney J 9:788–793

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Kong WY, Swaminathan R, Irish A (2013) Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature. Int Urol Nephrol 45:795–802

    Article  CAS  PubMed  Google Scholar 

  31. Michel PA, Dahan K, Ancel PY, Plaisier E, Mojaat R, De Seigneux S, Daugas E, Matignon M, Mesnard L, Karras A, François H, Pardon A, Caudwell V, Debiec H, Ronco P (2011) Rituximab treatment for membranous nephropathy: a French clinical and serological retrospective study of 28 patients. Nephron Extra 1:251–261

    Article  PubMed  PubMed Central  Google Scholar 

  32. Moroni G, Depetri F, Del Vecchio L, Gallelli B, Raffiotta F, Giglio E, Brunini F, D’Amico M, Longhi S, Radice A, Messa P, Sinico RA (2017) Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrol Dial Transplant 32:1691–1696

    CAS  PubMed  Google Scholar 

  33. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P (2002) Rituximab for idiopathic membranous nephropathy. Lancet 360:923–924

    Article  CAS  PubMed  Google Scholar 

  34. Roccatello D, Sciascia S, Di Simone D, Solfietti L, Naretto C, Fenoglio R, Baldovino S, Menegatti E (2016) New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: a prospective study and a review of the literature. Autoimmun Rev 15:529–538

    Article  CAS  PubMed  Google Scholar 

  35. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, Remuzzi G (2003) Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 14:1851–1857

    Article  CAS  PubMed  Google Scholar 

  36. Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pellé T, Gaspari F, Suardi F, Gagliardini E, Orisio S, Benigni A, Ronco P, Remuzzi G (2015) Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol 26:2545–2558

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Segarra A, Praga M, Ramos N, Polanco N, Cargol I, Gutierrez-Solis E, Gomez MR, Montoro B, Camps J (2009) Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol 4:1083–1088

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Souqiyyeh MZ, Shaheen FA, Alsuwaida A, Alghonaim M, Alwakeel J, Mosa D, Akhtar F, Rahman E, Husain M, Roujouleh H, Siddiqi N, Bukhari I, Sadaqa N, Mushtaque F, Awn NM, Shariya F, Alfi A, Amin M, Ahmad M, Rowaie FA, Almueilo S, Kechrid MC, Karkar A (2015) Rituximab as a rescue therapy in patients with glomerulonephritis. Saudi J Kidney Dis Transpl 26:47–55

    Article  PubMed  Google Scholar 

  39. Wang X, Cui Z, Zhang YM, Qu Z, Wang F, Meng LQ, Cheng XY, Liu G, Zhou FD, Zhao MH (2018) Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort. Nephrol Dial Transplant 33:1558–1563

    CAS  PubMed  Google Scholar 

  40. Zou PM, Li H, Cai JF, Chen ZJ, Li C, Li XW (2018) Therapy of rituximab in idiopathic membranous nephropathy with nephrotic syndrome: a systematic review and meta-analysis. Chin Med Sci J 33:9–19

    PubMed  Google Scholar 

  41. Rodas LM, Matas-García A, Barros X, Blasco M, Viñas O, Llobell A, Martin N, Quintana LF (2019) Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy. Clin Kidney J 12:36–41

    Article  CAS  PubMed  Google Scholar 

  42. Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F, Rambaldi A, Marasà M, Remuzzi G (2012) Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 23:1416–1425

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Ruggenenti P, Cravedi P, Sghirlanzoni MC, Gagliardini E, Conti S, Gaspari F, Marchetti G, Abbate M, Remuzzi G (2008) Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin J Am Soc Nephrol 3:1652–1659

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Nangaku M, Couser WG (2005) Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin Exp Nephrol 9:183–191

    Article  CAS  PubMed  Google Scholar 

  45. Tu WH, Petitti DB, Biava CG, Tulunay O, Hopper J Jr (1984) Membranous nephropathy: predictors of terminal renal failure. Nephron 36:118–124

    Article  CAS  PubMed  Google Scholar 

  46. van den Brand JAJG, Ruggenenti P, Chianca A, Hofstra JM, Perna A, Ruggiero B, Wetzels JFM, Remuzzi G (2017) Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy. J Am Soc Nephrol 28:2729–2737

    Article  PubMed  PubMed Central  Google Scholar 

  47. Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, Michel PA, Mihout F, Dussol B, Matignon M, Mousson C, Simon T, Ronco P (2017) GEMRITUX Study Group: rituximab for severe membranous nephropathy: A 6-month trial with extended follow-up. J Am Soc Nephrol 28:348–358

    Article  CAS  PubMed  Google Scholar 

  48. Branten AJ, Reichert LJ, Koene RA, Wetzels JF (1998) Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. QJM 91:359–366

    Article  CAS  PubMed  Google Scholar 

  49. Eriguchi M, Oka H, Mizobuchi T, Kamimura T, Sugawara K, Harada A (2009) Long-term outcomes of idiopathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone. Nephrol Dial Transplant 24:3082–3088

    Article  PubMed  Google Scholar 

  50. Mathrani V, Alejmi A, Griffin S, Roberts G (2017) Intravenous cyclophosphamide and oral prednisolone is a safe and effective treatment option for idiopathic membranous nephropathy. Clin Kidney J 10:450–454

    Article  PubMed  PubMed Central  Google Scholar 

  51. Ren S, Wang Y, Xian L, Toyama T, Jardine M, Li G, Perkovic V, Hong D (2017) Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: a network meta-analysis. PLoS ONE 12:e0184398

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Rojas-Rivera JE, Carriazo S, Ortiz A (2019) Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal. Clin Kidney J 12:629–638

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Affiliated Hospital of Chengde Medical University, 36 Nanyingzi St, Shuangqiao Qu, Chengde, 067000, Hebei, China

    Lan Huang, Qiao-Rong Dong, Ya-Juan Zhao & Gui-Cai Hu

Authors
  1. Lan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qiao-Rong Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ya-Juan Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gui-Cai Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gui-Cai Hu.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 73 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, L., Dong, QR., Zhao, YJ. et al. Rituximab for the management of idiopathic membranous nephropathy: a meta-analysis. Int Urol Nephrol 53, 111–119 (2021). https://doi.org/10.1007/s11255-020-02633-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-020-02633-5

Keywords

Search

Navigation